// App-Quantinova.ai

e16012 : 18F-FDG PET scan and liquid biopsy as tools to assess the pace of tumor progression and to predict overall survival (OS) in refractory colorectal cancer (rCRC): The CORIOLAN trial.

Researchers

Presenter

  • Silvia Camera

Principal Investigators

  • Erwin Woff

  • Pashalina Kehagias

  • Thomas Guiot

  • Gabriela Critchi

  • Giacomo Bregni

  • Elena Trevisi

  • Andrea Pretta

  • Amlie Deleruelle

  • Chiara Senti

  • Sophia Leduc

  • Leila Shaza

  • Frdric Hoerner

  • Caroline Vandeputte

  • Francesco Sclafani

  • Patrick Flamen

  • Alain Hendlisz

  • Amlie Deleporte

  • Francoise Rothe

Medical Centers

  • Gastrointestinal Unit, Department of Medical Oncology, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium

  • Data Centre, Institut Jules Bordet - Universite Libre de Bruxelles (ULB), Brussels, Belgium

  • Department of Medical Oncology, Institut Jules Bordet, LUniversite Libre de Bruxelles (U.L.B.), Bruxelles, Belgium

  • Clinical Trial Conduct Unit (CTCU), Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium

  • Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles (U.L.B.), Brussels, Belgium

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • 18F-fluorodeoxyglucose

  • Carcinoembryonic antigen

  • Circulating tumor cells

  • Plasma cell-free DNA

Drug/Treatment

  • Fludeoxyglucose (18F)

Outcome

  • N/A

Study Design

  • Single Arm

  • Prospective

Phase

  • NA

Study Id's

  • NCT01591590

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved